AS is suitable for low-risk prostate cancer or patients with <5 years life expectancy and in AS, physicians monitor patients closely and some periodic work- ups like DRE, PSA checking, prostate biopsy, and MRI are done, and every time the evidence is in favor of cancer progression, patients then become candidates for other definite treatments [80,84]. This evidence concerns the gene KLK3 and prostate cancer.